Page 1 | Search Results | Hematology, ASH Education Program

1-20 of 62

Sort by

Sort Order Select

Journal Articles

Treatment-naive CLL: lessons from phase 2 and phase 3 clinical trials

Jennifer A. Woyach

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 476–481.

https://doi.org/10.1182/hematology.2019001321

Published: 2019

Journal Articles

Clonal dynamics in chronic lymphocytic leukemia

Catherine Gutierrez, Catherine J. Wu

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 466–475.

https://doi.org/10.1182/hematology.2019000367

Published: 2019

Journal Articles

Relapsed CLL: sequencing, combinations, and novel agents

Jennifer R. Brown

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 248–255.

https://doi.org/10.1182/asheducation-2018.1.248

Published: 2018

Journal Articles

On the architecture of translational research designed to control chronic lymphocytic leukemia

Michael Hallek

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 1–8.

https://doi.org/10.1182/asheducation-2018.1.1

Published: 2018

Journal Articles

Cytotoxic therapy in acute myeloid leukemia: not quite dead yet

Laura C. Michaelis

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 51–62.

https://doi.org/10.1182/asheducation-2018.1.51

Published: 2018

Journal Articles

Richter transformation in the era of novel agents

Wei Ding

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 256–263.

https://doi.org/10.1182/asheducation-2018.1.256

Published: 2018

Journal Articles

Selecting Frontline Therapy for CLL in 2018

Nitin Jain

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 242–247.

https://doi.org/10.1182/asheducation-2018.1.242

Published: 2018

Journal Articles

The mutational landscape of chronic lymphocytic leukemia and its impact on prognosis and treatment

Gianluca Gaidano, Davide Rossi

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 329–337.

https://doi.org/10.1182/asheducation-2017.1.329

Published: 2017

Journal Articles

How should we sequence and combine novel therapies in CLL?

Matthew S. Davids

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 346–353.

https://doi.org/10.1182/asheducation-2017.1.346

Published: 2017

Journal Articles

Safety profiles of novel agent therapies in CLL

Inhye E. Ahn, Matthew S. Davids

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 354–357.

https://doi.org/10.1182/asheducation-2017.1.354

Published: 2017

Journal Articles

Optimizing frontline therapy of CLL based on clinical and biological factors

Kirsten Fischer, Michael Hallek

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 338–345.

https://doi.org/10.1182/asheducation-2017.1.338

Published: 2017

Journal Articles

Sequencing of chronic lymphocytic leukemia therapies

Jacqueline C. Barrientos

Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 128–136.

https://doi.org/10.1182/asheducation-2016.1.128

Published: 2016

Journal Articles

Novel agents in chronic lymphocytic leukemia

Nicole Lamanna, Susan O’Brien

Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 137–145.

https://doi.org/10.1182/asheducation-2016.1.137

Published: 2016

Journal Articles

Pure red cell aplasia

Robert T. Means, Jr

Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 51–56.

https://doi.org/10.1182/asheducation-2016.1.51

Published: 2016

Journal Articles

First-line therapy for young patients with CLL

Nitin Jain, Susan O’Brien

Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 146–148.

https://doi.org/10.1182/asheducation-2016.1.146

Published: 2016

Journal Articles

Prognostication of chronic lymphocytic leukemia in the era of new agents

Barbara Eichhorst, Michael Hallek

Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 149–155.

https://doi.org/10.1182/asheducation-2016.1.149

Published: 2016

Journal Articles

Treatment of patients with transformed lymphoma

Silvia Montoto

Hematology Am Soc Hematol Educ Program (2015) 2015 (1): 625–630.

https://doi.org/10.1182/asheducation-2015.1.625

Published: 2015

Journal Articles

Patterns of resistance to B cell–receptor pathway antagonists in chronic lymphocytic leukemia and strategies for management

Jennifer A. Woyach

Hematology Am Soc Hematol Educ Program (2015) 2015 (1): 355–360.

https://doi.org/10.1182/asheducation-2015.1.355

Published: 2015

Journal Articles

Prognostic markers and standard management of chronic lymphocytic leukemia

Stephan Stilgenbauer

Hematology Am Soc Hematol Educ Program (2015) 2015 (1): 368–377.

https://doi.org/10.1182/asheducation-2015.1.368

Published: 2015

Journal Articles

Mutations in chronic lymphocytic leukemia and how they affect therapy choice: focus on NOTCH1 , SF3B1 , and TP53

Clive S. Zent, W. Richard Burack

Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 119–124.

https://doi.org/10.1182/asheducation-2014.1.119

Published: 2014

NARROW

Treatment-naive CLL: lessons from phase 2 and phase 3 clinical trials

Clonal dynamics in chronic lymphocytic leukemia

Relapsed CLL: sequencing, combinations, and novel agents

On the architecture of translational research designed to control chronic lymphocytic leukemia

Cytotoxic therapy in acute myeloid leukemia: not quite dead yet

Richter transformation in the era of novel agents

Selecting Frontline Therapy for CLL in 2018

The mutational landscape of chronic lymphocytic leukemia and its impact on prognosis and treatment

How should we sequence and combine novel therapies in CLL?

Safety profiles of novel agent therapies in CLL

Optimizing frontline therapy of CLL based on clinical and biological factors

Sequencing of chronic lymphocytic leukemia therapies

Novel agents in chronic lymphocytic leukemia

Pure red cell aplasia

First-line therapy for young patients with CLL

Prognostication of chronic lymphocytic leukemia in the era of new agents

Treatment of patients with transformed lymphoma

Patterns of resistance to B cell–receptor pathway antagonists in chronic lymphocytic leukemia and strategies for management

Prognostic markers and standard management of chronic lymphocytic leukemia

Mutations in chronic lymphocytic leukemia and how they affect therapy choice: focus on NOTCH1 , SF3B1 , and TP53

ASH Publications

American Society of Hematology

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only